%0 Journal Article
%T Pharmacokinetics and safety of deltoid or gluteal injection of
aripiprazole lauroxil NanoCrystal£¿ Dispersion used for initiation of
the long-acting antipsychotic aripiprazole lauroxil
%A Angela Wehr
%A David P. Walling
%A John Sonnenberg
%A Lisa von Moltke
%A Marjie L. Hard
%A Sarah Farwick
%A Yangchun Du
%J Archive of "Therapeutic Advances in Psychopharmacology".
%D 2019
%R 10.1177/2045125319859964
%X Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21£¿days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal£¿ Dispersion formulation of AL (ALNCD) and a single dose of 30£¿mg oral aripiprazole. This phase I study assessed the pharmacokinetics and safety of deltoid versus gluteal ALNCD injections
%K ALNCD
%K antipsychotic
%K aripiprazole lauroxil
%K aripiprazole
%K bioavailability
%K initiation regimen
%K injection site
%K long-acting injectable
%K pharmacokinetics
%K safety/tolerability
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607563/